Literature DB >> 12700467

Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.

Maria Paola Trotta1, Adriana Ammassari, Alessandro Cozzi-Lepri, Mauro Zaccarelli, Francesco Castelli, Pasquale Narciso, Sara Melzi, Andrea De Luca, Antonella D'Arminio Monforte, Andrea Antinori.   

Abstract

The difference between adherence to non- nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)-based regimens was investigated. Better adherence was found in NNRTI-treated patients, especially when efavirenz was included in the regimen, compared with single PI-treated patients and in those with CD4 cell counts less than 200 x 10(6)/l. By contrast, younger age, self-report of active drug use, fatigue or vomiting negatively affected adherence. Self-reported sexual dysfunction was significantly associated with non-adherence only in PI-treated individuals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700467     DOI: 10.1097/00002030-200305020-00026

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

Review 1.  Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.

Authors:  Jane M Simoni; Ann E Kurth; Cynthia R Pearson; David W Pantalone; Joseph O Merrill; Pamela A Frick
Journal:  AIDS Behav       Date:  2006-05

2.  Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Akihiko Saitoh; Stephen A Spector
Journal:  Futur HIV Ther       Date:  2008-01-01

3.  The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients.

Authors:  Allison J Applebaum; Laura C Reilly; Jeffrey S Gonzalez; Mark A Richardson; Catherine L Leveroni; Steven A Safren
Journal:  AIDS Patient Care STDS       Date:  2009-06       Impact factor: 5.078

4.  One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects.

Authors:  Monica Airoldi; Mauro Zaccarelli; Luca Bisi; Teresa Bini; Andrea Antinori; Cristina Mussini; Francesca Bai; Giancarlo Orofino; Laura Sighinolfi; Andrea Gori; Fredy Suter; Franco Maggiolo
Journal:  Patient Prefer Adherence       Date:  2010-05-13       Impact factor: 2.711

Review 5.  Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials.

Authors:  Yazdan Yazdanpanah; Daouda Sissoko; Matthias Egger; Yves Mouton; Marcel Zwahlen; Geneviève Chêne
Journal:  BMJ       Date:  2004-01-23

6.  Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen.

Authors:  Giorgio L Colombo; Sergio Di Matteo; Franco Maggiolo
Journal:  Clinicoecon Outcomes Res       Date:  2013-02-12

Review 7.  Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Authors:  Jeffrey S Barrett; Line Labbé; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology Issues, and Clinical Management.

Authors:  Marco de Tubino Scanavino
Journal:  Adv Urol       Date:  2011-10-20

9.  Quality of life in HIV clinical trials: why sexual health must not be ignored.

Authors:  Olivier Koole; Christiana Noestlinger; Robert Colebunders
Journal:  PLoS Clin Trials       Date:  2007-03-02

Review 10.  The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis.

Authors:  Imad Al-Dakkak; Seema Patel; Eilish McCann; Abhijit Gadkari; Girish Prajapati; Eric M Maiese
Journal:  AIDS Care       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.